INVO BioScience,INC Stock Price, News & Analysis

INVO Bioscience, Inc. (NASDAQ: INVO) announced the appointment of Rebecca Messina to its board of directors, effective immediately. Messina brings extensive marketing experience from firms like Uber and Coca-Cola, focusing on brand building and strategic growth. CEO Steve Shum highlighted that her appointment aligns with the company's mission to enhance access to fertility treatment globally through its innovative device, INVOcell®, which offers a cost-effective alternative to traditional methods. Messina expressed her commitment to broadening awareness of fertility options.

INVO Bioscience (NASDAQ: INVO) announced its support for RESOLVE: The National Infertility Association during National Infertility Awareness Week (April 18-24). The company focuses on providing affordable infertility treatments with its INVOcell®, the only in vivo Intravaginal Culture System. CEO Steve Shum emphasized the importance of increasing access to care for the underserved patient population facing infertility challenges. RESOLVE advocates for equal access to family building options and connects individuals with resources for infertility.

INVO Bioscience (NASDAQ: INVO) has announced a partnership with Lyfe Medical to expand the accessibility of its INVOcell infertility treatment in Northern California, home to approximately 8 million residents. Under the agreement, Lyfe Medical will operate a clinic in the San Francisco Bay Area, while INVO Bioscience will establish an embryology center to support the INVO procedure. The partnership aims to address challenges in affordability and capacity within the infertility treatment sector, enhancing patient access to care.

INVO Bioscience, a medical device company specializing in infertility treatments, announced that CEO Steve Shum will present at the Tribe Public Webinar titled "Democratizing Infertility - A Severely Underserved Global Market". This event will be held on April 13, 2021, at 8:30 am Pacific / 11:30 am Eastern. Attendees can register for the complimentary webinar via INVO.TribePublic.com and submit questions to management either beforehand or during the session.

INVO Bioscience, Inc. (NASDAQ: INVO) reported a revenue of $1.04 million for 2020, down from $1.48 million in 2019, with a net loss of $8.3 million driven by higher operating expenses. The company announced plans to open its first U.S. INVOcell clinic in Birmingham, Alabama, in partnership with experienced reproductive specialists, with additional clinics planned in Mexico and India. A $501,000 purchase order from Ferring, placed in March 2021, will boost revenue in Q1. Cash reserves stand at $10.1 million, reflecting a significant increase from $1.2 million in 2019.

INVO Bioscience (NASDAQ: INVO) announced its participation in the Lytham Partners Spring 2021 Investor Conference on April 1, 2021, at 4:15 PM ET. The company specializes in the INVOcell®, the world's first in vivo Intravaginal Culture System designed for infertility treatments. A webcast of the presentation will be accessible on the company's website and archived for later viewing. Management will engage in virtual one-on-one meetings during the conference period from March 30 to April 1, 2021. For details, visit invobioscience.com.

INVO Bioscience (NASDAQ: INVO) is set to report its fourth quarter and fiscal year 2020 financial results on March 30, 2021, after market close. The company specializes in developing the INVOcell®, the only in vivo Intravaginal Culture System (IVC) designed to assist patients with infertility. A conference call will be held on the same day at 4:30 pm ET for a comprehensive review of the outcomes. The aim of INVO is to provide affordable and effective treatments for infertility, leveraging their innovative procedures and technology.

INVO Bioscience, Inc. (NASDAQ: INVO) has signed a 50/50 joint venture agreement with reproductive specialists to establish the first INVO-exclusive clinic in the U.S. located in Birmingham, Alabama. This clinic aims to enhance the accessibility and affordability of infertility treatment using the INVOcell, an innovative in vivo Intravaginal Culture System. Operations are expected to begin in the second half of 2021. The collaboration with experienced professionals is anticipated to drive adoption of the INVOcell technology, potentially benefiting many underserved patients.

INVO Bioscience (NASDAQ: INVO), a medical device company specializing in infertility treatments, will participate in the 33rd Annual ROTH Conference held virtually from March 15-17, 2021. The company will engage in one-on-one meetings with investors and analysts to discuss its innovative product, INVOcell, the only in vivo Intravaginal Culture System. This product offers a more affordable and natural approach to infertility treatment compared to traditional methods like IVF. An investor presentation will be available at their website.